A drug from Biogen on Friday became the first approved therapy for a rare and devastating genetic disease, giving hope to patients and marking a major milestone for a biotech giant at a crossroads.

The therapy, Spinraza, is meant to treat an inherited disorder called spinal muscular atrophy by tinkering with a defective gene. Children born with the disease don’t make enough of a protein called SMN, which is key to motor development. Spinraza works by amplifying the gene responsible for SMN, thereby boosting its production. The FDA approved the drug to treat both children and adults.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

  • Hello, I am living in Turkey, a womanizer Text. And I have a child with SMA type 1 patients.My child is 5 months old, I’m asking you to help me. You produce the “Spinoza” (nusiner if I want to get information from you about a drug named.Please help me.People with this condition in the whole world you are the hope of.What is the price of this medication ? I’d appreciate it if you notify me with an email. I wish successful work, thanks

Sign up for our Daily Recap newsletter

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy